(R)-[11C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP

Nuclear Medicine and Biology

Volumn 40, Issue 7, 2013, Pages 873-878

  Römermann, Kerstin ^a,b   Wanek, Thomas ^c   Bankstahl, Marion ^a   Bankstahl, Jens P ^d   Fedrowitz, Maren ^a   Müller, Markus ^b   Löscher, Wolfgang ^a   Kuntner, Claudia ^c   Langer, Oliver ^b,c  

^a CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c AIT AUSTRIAN INSTITUTE OF TECHNOLOGY   (Austria)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

(R) 11C verapamil; Blood brain barrier; Breast cancer resistance protein; Multidrug resistance protein 1; P glycoprotein; Positron emission tomography

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARBON VERAPAMIL C 11; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG TRANSPORT; DRUG UPTAKE; ENANTIOSELECTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE TRACING; KNOCKOUT MOUSE; LIMIT OF QUANTITATION; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOISOTOPE DISTRIBUTION; TISSUE DISTRIBUTION; WILD TYPE;

(R)-[(11)C]VERAPAMIL; BLOOD-BRAIN BARRIER; BREAST CANCER RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; P-GLYCOPROTEIN; POSITRON EMISSION TOMOGRAPHY;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CARBON RADIOISOTOPES; DOGS; FEMALE; GENE KNOCKOUT TECHNIQUES; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; MICE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; POSITRON-EMISSION TOMOGRAPHY; VERAPAMIL;

EID: 84883551313     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.05.012     Document Type: Article

References (36)

1. Hendrikse N.H., Schinkel A.H., de Vries E.G., Fluks E., Van der Graaf W.T., Willemsen A.T., et al. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol 1998, 124(7):1413-1418.
2. 11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. Nucl Med Biol 2003, 30(7):747-751.
3. Sasongko L., Link J.M., Muzi M., Mankoff D.A., Yang X., Collier A.C., et al. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 2005, 77(6):503-514.
4. 11C]verapamil. J Pharmacol Exp Ther 2006, 316(2):647-653.
5. Syvänen S., Blomquist G., Sprycha M., Urban Hoglund A., Roman M., Eriksson O., et al. Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET. Neuroimage 2006, 32(3):1134-1141.
6. 11C-verapamil and PET. J Nucl Med 2009, 50(12):1954-1961.
7. 11C]verapamil PET. Eur J Nucl Med Mol Imaging 2010, 37(5):942-953.
8. 11C]verapamil. Epilepsia 2007, 48(9):1774-1784.
9. van Assema D.M., Lubberink M., Bauer M., van der Flier W.M., Schuit R.C., Windhorst A.D., et al. Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain 2012, 135(Pt 1):181-189.
10. Kortekaas R., Leenders K.L., van Oostrom J.C., Vaalburg W., Bart J., Willemsen A.T., et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 2005, 57(2):176-179.
11. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981, 41(5):1967-1972.
12. Warr J.R., Anderson M., Fergusson J. Properties of verapamil-hypersensitive multidrug-resistant Chinese hamster ovary cells. Cancer Res 1988, 48(16):4477-4483.
13. Pauli-Magnus C., von Richter O., Burk O., Ziegler A., Mettang T., Eichelbaum M., et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther 2000, 293(2):376-382.
14. Shirasaka Y., Sakane T., Yamashita S. Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J Pharm Sci 2008, 97(1):553-565.
15. Löscher W., Luna-Tortós C., Römermann K., Fedrowitz M. Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected. Curr Pharm Des 2011, 17(26):2808-2828.
16. Germann U.A., Ford P.J., Shlyakhter D., Mason V.S., Harding M.W. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs 1997, 8(2):141-155.
17. Loe D.W., Deeley R.G., Cole S.P. Verapamil stimulates glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). J Pharmacol Exp Ther 2000, 293(2):530-538.
18. Perrotton T., Trompier D., Chang X.B., Di Pietro A., Baubichon-Cortay H. (R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1. J Biol Chem 2007, 282(43):31542-31548.
19. Matsson P., Englund G., Ahlin G., Bergström C.A., Norinder U., Artursson P. A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2). J Pharmacol Exp Ther 2007, 323(1):19-30.
20. Crivellato E., Candussio L., Rosati A.M., Bartoli-Klugmann F., Mallardi F., Decorti G. The fluorescent probe Bodipy-FL-verapamil is a substrate for both P-glycoprotein and multidrug resistance-related protein (MRP)-1. J Histochem Cytochem 2002, 50(5):731-734.
21. Bankstahl J.P., Bankstahl M., Römermann K., Wanek T., Stanek J., Windhorst A.D., et al. Tariquidar and elacridar are dose-dependently transported by p-glycoprotein and bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study. Drug Metabol Dispos 2013, 41(4):754-762.
22. Sane R., Agarwal S., Mittapalli R.K., Elmquist W. Saturable active efflux by P-gp and Bcrp at the blood-brain barrier leads to non-linear distribution of elacridar to the central nervous system. J Pharmacol Exp Ther 2013, 345(1):111-124.
23. Wanek T., Kuntner C., Bankstahl J.P., Mairinger S., Bankstahl M., Stanek J., et al. A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier. J Cereb Blood Flow Metab 2012, 32(11):2002-2011.
24. Baltes S., Fedrowitz M., Luna-Tortós C., Potschka H., Löscher W. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther 2007, 320(1):331-343.
25. Luna-Tortós C., Fedrowitz M., Löscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 2008, 55(8):1364-1375.
26. Luna-Tortós C., Fedrowitz M., Löscher W. Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology 2010, 58(7):1019-1032.
27. Brunner M., Langer O., Sunder-Plassmann R., Dobrozemsky G., Müller U., Wadsak W., et al. Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin Pharmacol Ther 2005, 78(2):182-190.
28. Kannan P., Brimacombe K.R., Zoghbi S.S., Liow J.S., Morse C., Taku A.K., et al. N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier. Drug Metabol Dispos 2010, 38(6):917-922.
29. Poller B., Wagenaar E., Tang S.C., Schinkel A.H. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm 2011, 8(2):571-582.
30. Uchida Y., Ohtsuki S., Katsukura Y., Ikeda C., Suzuki T., Kamiie J., et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 2011, 117(2):333-345.
31. Sugiyama D., Kusuhara H., Lee Y.J., Sugiyama Y. Involvement of multidrug resistance associated protein 1 (Mrp1) in the efflux transport of 17beta estradiol-d-17beta-glucuronide (E217betaG) across the blood-brain barrier. Pharm Res 2003, 20(9):1394-1400.
32. Okamura T., Kikuchi T., Okada M., Toramatsu C., Fukushi K., Takei M., et al. Noninvasive and quantitative assessment of the function of multidrug resistance-associated protein 1 in the living brain. J Cereb Blood Flow Metab 2009, 29(3):504-511.
33. de Lange E.C. Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. Adv Drug Deliv Rev 2004, 56(12):1793-1809.
34. 11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. Nucl Med Biol 2005, 32(1):87-93.
35. Kodaira H., Kusuhara H., Ushiki J., Fuse E., Sugiyama Y. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J Pharmacol Exp Ther 2010, 333(3):788-796.
36. Tournier N., Valette H., Peyronneau M.A., Saba W., Goutal S., Kuhnast B., et al. Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening. J Nucl Med 2011, 52(3):415-423.